Amicogen Inc is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâ€™s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company sells its products in domestic and overseas markets.

Employees

236

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/06/26	₩1,527.00	+4.16%	521,421
26/06/26	₩1,466.00	-9.78%	1,191,225
25/06/26	₩1,625.00	-4.07%	935,325
24/06/26	₩1,694.00	-2.08%	1,426,922
23/06/26	₩1,730.00	+17.37%	6,481,010

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 29/06/2026			5-day change	1st Jan Change
1,527.00 ^KRW	+4.16%		+3.60%	-14.31%

06-21	Amicogen, Inc. announced that it expects to receive KRW 9.999998911 billion in funding	CI
05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	108B 69.73M 61.06M 56.37M 52.64M 99.09M 6.59B 101M 678M 262M 3.25B 262M 256M 11.29B	P/E 2024	-4.02x	P/E 2025	-3.28x
Enterprise Value	194B 126M 110M 102M 95.16M 179M 11.92B 183M 1.23B 473M 5.88B 473M 463M 20.41B	EV / Sales 2024	1.86x	EV / Sales 2025	4.43x
Free-Float	95.13%	Yield 2024 *	-	Yield 2025	-

06-21	Amicogen, Inc. announced that it expects to receive KRW 9.999998911 billion in funding	CI
05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
21/09/25	Amicogen, Inc.(KOSDAQ:A092040) added to S&P Global BMI Index	CI
20/08/25	Bio-Works Launches WorkBeads AffimAb Edge: Strategic Expansion in the Protein A Resin Market	CI
14/08/25	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/08/25	Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.	CI
14/05/25	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
24/04/25	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI
19/03/25	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
09/12/24	An undisclosed buyer agreed to acquire an unknown stake in Amicogen Biopharm Co., Ltd. from Amicogen, Inc. for KRW 54.7 billion.	CI
20/11/24	Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc..	CI

20/06/24	Bio-Works and Amicogen have concluded their technology transfer project.	AQ
10/09/21	Bio Works Technologies : Amicogen Inc enters into agreement to divest its ownership in Bio-Works	AQ
17/02/21	Bio Works Technologies : Works signs licensing agreement with Amicogen Inc to establish local manufacturing of agarose resins in South Korea	AQ

Amicogen, Inc. Share Price

Stocks

A092040

KR7092040005

Biotechnology & Medical Research

Valuation: Amicogen, Inc.

Chart: Amicogen, Inc.

Latest news : Amicogen, Inc.

Press Releases: Amicogen, Inc.

News in other languages: Amicogen, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Amicogen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+4.16%
1 week	+3.60%
Current month	-3.05%
1 month	-3.05%
3 months	-16.51%
6 months	-14.07%
Current year	-14.31%

1 week	1,433	1,795
1 month	1,218	1,890
Current year	1,160	2,300
1 year	1,160	4,440
3 years	1,160	9,790
5 years	1,160	23,500
10 years	1,160	24,825

Manager	Title	Age	Since
Jjeo Pyo CEO	Chief Executive Officer	53	-
Young-Chul Yoon PRN	Corporate Officer/Principal	55	27/03/2024
Chun-Gu Kim AUD	Comptroller/Controller/Auditor	69	26/03/2025

Director	Title	Age	Since
Jun-Ho Kim BRD	Director/Board Member	56	25/02/2025
Jjeo Pyo BRD	Director/Board Member	53	-
Young-Chul Yoon BRD	Director/Board Member	55	27/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-02	Ji-Seong So	Buy	Director	435	0.0006%
03-02	Young-Chul Yoon	Buy	Director	109	0.0002%
02-26	Eun-seong Hwang	Buy		4,000	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICOGEN, INC.	+4.16%	+3.60%	-58.51%	-83.59%	69.73M
ARGENX SE	+2.34%	-1.35%	+70.71%	+125.66%	55.78B
WUXI APPTEC CO., LTD.	+6.76%	+18.10%	+91.66%	+104.09%	55.66B
BIONTECH SE	-0.50%	+3.45%	-11.95%	-13.14%	23.84B
INSMED INCORPORATED	+2.11%	+4.97%	+6.55%	+408.20%	22.7B
GENMAB A/S	+5.66%	+6.29%	+38.10%	-29.61%	16.12B
EXELIXIS, INC.	-0.14%	+6.09%	+23.57%	+185.01%	13.64B
PHARMAESSENTIA CORPORATION	+9.96%	+15.98%	+157.65%	+310.89%	14.8B
MADRIGAL PHARMACEUTICALS, INC.	+1.07%	+3.53%	+75.64%	+130.11%	12.16B
CYTOKINETICS, INCORPORATED	-0.41%	+8.57%	+162.91%	+166.29%	11.85B
Average	+3.08%	+5.49%	+55.63%	+130.39%	22.66B
Weighted average by Cap.	+3.42%	+7.70%	+66.30%	+140.99%

	2024	2025
Net sales	174B 113M 98.53M 90.96M 84.94M 160M 10.64B 164M 1.09B 423M 5.25B 423M 413M 18.22B	41.98B 27.21M 23.83M 22M 20.54M 38.67M 2.57B 39.55M 265M 102M 1.27B 102M 99.95M 4.41B
Net income	-52.79B -34.22M -29.96M -27.66M -25.83M -48.62M -3.24B -49.73M -333M -129M -1.6B -129M -126M -5.54B	-29.96B -19.42M -17M -15.7M -14.66M -27.59M -1.84B -28.22M -189M -72.93M -906M -72.93M -71.33M -3.14B
Net Debt	112B 72.29M 63.29M 58.43M 54.56M 103M 6.83B 105M 703M 271M 3.37B 271M 266M 11.71B	86.91B 56.33M 49.33M 45.54M 42.52M 80.05M 5.33B 81.87M 548M 212M 2.63B 212M 207M 9.12B